Yale RDRC – Yale University Radioactive Drug Research Committee
The Yale University Radioactive Drug Research Program (Yale RDRC) program operates under federal regulation 21 CFR 361.1, which permits review and monitoring of basic research using radioactive drugs in humans without an IND when the drug is administered under specific conditions. These specific conditions are outlined in detail on the Food & Drug Administration (FDA) website.
For more information regarding the U.S. Food & Drug Administration (FDA) Radioactive Drug Research Communittee (RDRC) Program, please refer to the following information located on the FDA website.
For questions regarding the application process, approvals and/or future committee meeting dates and deadlines, please contact Donna McMahon at RDRC_admin@yale.edu.